查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1990072

霍乱疫苗市场：2026-2032年全球市场预测（依疫苗类型、给药途径、剂型、包装、年龄层、应用、最终用户和分销管道划分）

Cholera Vaccines Market by Vaccine Type, Route Of Administration, Dosage Form, Presentation Type, Age Group, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，霍乱疫苗市值将达到 3.2981 亿美元，到 2026 年将成长至 3.5318 亿美元，到 2032 年将达到 5.4959 亿美元，复合年增长率为 7.56%。

主要市场统计数据
基准年 2025 3.2981亿美元
预计年份：2026年 3.5318亿美元
预测年份 2032 5.4959亿美元
复合年增长率 (%) 7.56%

为公共卫生领导者和产业相关人员提供权威的介绍，概述了霍乱疫苗的最新发展、供应挑战和策略重点。

霍乱仍然是全球公共卫生关注的焦点，而不断发展的疫苗模式对于预防和控制疫情至关重要。本执行摘要整合了产品创新、监管环境、通路和相关人员采纳方面的关键进展，旨在为公共卫生领导者、生产商和投资者提供资讯。它简洁地概述了霍乱疫苗技术的现状、影响疫苗取得和供应的因素，以及指导采购和部署的实际考虑。

疫苗配方创新、适应性监管途径以及对加速疫苗部署和普及的计划的期望不断变化，正在推动疫苗领域发生显着变化。

霍乱疫苗领域正经历一场变革，其驱动力包括科学创新、新的政策重点以及供应链结构的改进。製剂技术的进步使得口服製剂更加稳定，部分产品的耐热性也提升。这减轻了低温运输的负担，并拓宽了可行的经销模式。同时，一些地区的监管路径也变得更加灵活，加快了在疫情中展现出显着疗效的疫苗的审查。

分析美国将于 2025 年推出的新关税对供应链、供应商选择和采购惯例。

美国2025年实施的关税政策为全球霍乱疫苗生态系统中的製造商、经销商和采购负责人带来了新的营运考量。进口关税及相关合规要求的变化正在影响某些零件和成品的成本结构，促使供应链相关人员重新审视筹资策略以及与国际合作伙伴的合约条款。为此，一些製造商正加强提高零件的本地化生产，并对替代供应商进行认证，以维持供应的连续性并降低关税变化带来的风险。

基于详细细分的洞察揭示了疫苗类型、给药途径、配方、剂型、分销、最终用户、年龄层和应用如何决定产品类型和方案选择。

细分市场洞察揭示了产品特性和给药方式如何影响临床效用、商业策略和专案适用性。根据疫苗类型，该领域区分注射剂和口服疫苗，每种疫苗都有其独特的临床、物流和接受度的考量。注射剂疫苗适用于寻求持久免疫反应的临床环境，而口服疫苗通常优先考虑大规模免疫接种宣传活动和快速疫情应对中的便捷给药方式。根据给药途径，肌肉注射和口服给药之间的差异会影响医护人员培训、病患接受度和医疗服务场所的选择。肌肉注射通常需要经过训练的人员和医疗废弃物锐器管理，而口服给药则可减轻这些操作负担，并扩大社区宣传活动的覆盖范围。

影响美洲、欧洲、中东和非洲以及亚太地区监管方式、采购模式、製造合作和部署策略的区域趋势。

区域趋势对霍乱疫苗接种计画的政策重点、监管方式和供应链发展有显着影响。在美洲，公共卫生系统倾向于优先将疫苗纳入既定的免疫接种计划，并制定应对局部疫情的紧急时应对计画，同时辅以强调透明合约和集中分发的公共采购框架。相较之下，在欧洲、中东和非洲（EMEA）地区，由于法规环境和卫生系统能力存在差异，区域协调机制和捐助者资助的倡议在确保疫苗取得平等和规范紧急应变通讯协定发挥重要作用。

企业策略方向和伙伴关係模式，透过製造规模、平台创新和对专案支援的承诺来定义竞争优势。

主要企业之间的竞争格局反映了它们在创新、供应合约以及与公共卫生组织伙伴关係方面的不同策略。一些组织优先投资于能够快速迭代开发口服和注射疫苗候选产品的平台，而其他组织则专注于优化生产流程，并扩大填充和包装能力，以满足大规模宣传活动的需求。商业製造商与全球卫生组织之间的策略联盟日益普遍，其重点在于共同努力，确保疫苗价格合理、供应稳定，并能惠及服务不足的人。

为製造商和公共卫生合作伙伴制定可操作的、优先考虑的策略行动，以协调产品设计、供应弹性、定价和专案支持，从而产生最大影响。

针对产业领导者的实际建议强调，应将科学研发与实际供应链和相关人员合作结合。首先，应优先考虑产品设计决策，充分考虑最终用户需求和分销实际情况，透过配方和包装选择来减少物流摩擦，从而支持对感染疾病疫情的快速反应。其次，应投资于多元化的供应商网路和区域製造合作伙伴关係，以减轻贸易和关税的影响，同时增强应对力。第三，应将培训、低温运输创新和部署后监测等项目支援整合到商业性伙伴关係中，并加强与卫生部门和采购负责人的关係。

结合专家访谈、文献整合和三角测量分析的稳健混合方法研究框架，确保了基于证据的、可操作的见解。

本报告的调查方法采用混合式研究方法，结合了全面的文献整合、专家访谈以及对政策和采购文件的定性分析。主要研究包括与疫苗研发人员、供应链专家和免疫专案管理人员进行结构化咨询，以收集有关营运挑战和机会的第一手观点。次要研究则整合了同行评审的研究、监管文件和专案指南，以支持报告主题并确保说明基于证据。

这些具有前瞻性的结论强调了创新、供应韧性和相关人员合作的必要整合，才能将疫苗研发进展转化为公共卫生成果。

总之，霍乱疫苗领域正处于一个转折点，科学进步、供应链现代化和不断变化的政策需求相互交织，重塑疫苗的研发、采购和分发方式。配方和给药方法的创新拓展了公共卫生工作者可用的工具，而贸易和采购惯例的改变则凸显了各相关人员相关者运作灵活性的必要性。因此，能够整合卓越技术、切实有效的专案支援和稳健的商业策略的组织才能最终取得成功。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：霍乱疫苗市场：依疫苗类型划分

  • 注射疫苗
  • 口服疫苗

第九章：霍乱疫苗市场：依给药途径划分

  • 肌肉内部
  • 口服

第十章：霍乱疫苗市场：以剂型划分

  • 液体
  • 冷冻干燥

第十一章 霍乱疫苗市场：依包装类型划分

  • 多次给药
  • 单一剂量

第十二章：霍乱疫苗市场：依年龄组别划分

  • 成人版
  • 老年人
  • 儿童

第十三章：霍乱疫苗市场：依应用领域划分

  • 为了预防
  • 治疗

第十四章 霍乱疫苗市场：依最终用户划分

  • 门诊部
  • 诊所
  • 医院
  • 研究设施

第十五章：霍乱疫苗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十六章 霍乱疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章 霍乱疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章 霍乱疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章：美国：霍乱疫苗市场

第二十章：中国：霍乱疫苗市场

第21章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech International Limited
  • Emergent BioSolutions Inc.
  • EuBiologics Co. Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • PaxVax Inc.
  • Pfizer Inc.
  • Sanofi Pasteur SA
  • Serum Institute of India Pvt. Ltd.
  • Shantha Biotechnics Limited
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
Product Code: MRR-5D693B46BD1B

The Cholera Vaccines Market was valued at USD 329.81 million in 2025 and is projected to grow to USD 353.18 million in 2026, with a CAGR of 7.56%, reaching USD 549.59 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 329.81 million
Estimated Year [2026] USD 353.18 million
Forecast Year [2032] USD 549.59 million
CAGR (%) 7.56%

An authoritative introduction that frames current cholera vaccine advancements, delivery challenges, and strategic priorities for public health leaders and industry stakeholders

Cholera remains a global public health concern, and the evolving landscape of vaccines is central to prevention and outbreak control strategies. This executive summary synthesizes critical developments across product innovation, regulatory progress, distribution channels, and stakeholder adoption to inform public health leaders, manufacturers, and investors. It provides a concise but comprehensive orientation to the current state of cholera vaccine technologies, the forces reshaping access and delivery, and the practical considerations that guide procurement and deployment.

In the following pages, readers will find context on vaccine types, administration routes, formulation choices, presentation formats, and end-user settings, as well as the implications of geopolitical and trade dynamics. The summary is designed to be actionable: it highlights where scientific advances intersect with programmatic realities and where commercial opportunities align with public health priorities. By framing these themes up front, decision-makers can rapidly identify candidate areas for deeper investigation and immediate action.

Compelling landscape shifts driven by formulation innovation, adaptive regulatory pathways, and evolving programmatic expectations that accelerate vaccine deployment and access

The cholera vaccine landscape is undergoing transformative shifts driven by scientific innovation, renewed policy attention, and improvements in supply chain architecture. Advances in formulation science have enabled more stable oral preparations and improved thermostability for some products, which in turn ease cold-chain burdens and broaden the range of feasible distribution models. Parallel to these technological changes, regulatory pathways have become more adaptive in several jurisdictions, facilitating accelerated reviews for vaccines that demonstrate demonstrable benefits in outbreak contexts.

At the same time, stakeholder expectations are evolving. Public health authorities increasingly demand evidence of real-world effectiveness and programmatic suitability, not just immunogenicity. Funders and procurement agencies are prioritizing vaccines that can be deployed quickly in emergency settings and that integrate into routine immunization programs. Consequently, manufacturers are balancing investment between novel platforms and incremental improvements to existing oral and injectable offerings. Taken together, these shifts are reshaping competitive dynamics, opening new channels for collaboration, and elevating the importance of integrated planning across clinical, regulatory, and supply functions.

Analysis of the operational and strategic effects of newly implemented United States tariffs in 2025 on supply chains, sourcing choices, and procurement practices

Tariff policies enacted by the United States in 2025 have introduced additional operational considerations for manufacturers, distributors, and procurers engaged in the global cholera vaccine ecosystem. Changes in import duties and related compliance requirements have affected the cost profile of certain components and finished products, prompting supply chain stakeholders to reassess sourcing strategies and contractual terms with international partners. In response, some manufacturers have intensified efforts to localize component production or to qualify alternative suppliers to maintain continuity of supply and to mitigate exposure to tariff volatility.

Furthermore, procurement teams and international agencies have adapted tender structures and pricing negotiations to reflect the new trade environment. These adaptations include longer-term supply agreements with clearer allocation terms and contingency clauses that address tariff-related cost fluctuations. Importantly, the tariff adjustments have also underscored the value of supply chain transparency and traceability, encouraging greater investment in analytics and scenario planning to preserve programmatic resilience. While tariffs represent a macro-level shift, their most tangible impacts emerge through operational changes at manufacturing sites, distribution hubs, and procurement desks.

Deep segmentation-driven insights revealing how vaccine type, administration route, formulation, presentation, distribution, end-user, age group, and application determine product and program choices

Segmentation insights illuminate how product attributes and delivery contexts shape clinical utility, commercial strategy, and programmatic fit. Based on vaccine type, the field differentiates between injectable vaccine options and oral vaccine formulations, with each pathway carrying distinct clinical, logistical, and acceptance considerations; injectable vaccines may align with clinical settings seeking durable immune responses, whereas oral vaccines often prioritize ease of administration during mass campaigns and rapid outbreak response. Based on route of administration, distinctions between intramuscular and oral delivery influence provider training, patient acceptance, and site-of-care selection; intramuscular routes typically require trained personnel and sharps management, while oral administration reduces those operational burdens and can expand reach in community campaigns.

Based on dosage form, liquid and lyophilized presentations present trade-offs related to stability, reconstitution requirements, and cold-chain dependencies; liquid forms facilitate rapid deployment, while lyophilized formulations can extend shelf life under certain storage profiles. Based on presentation type, multi dose and single dose packaging choices affect wastage rates, storage space, and per-administration cost dynamics; multi dose vials may improve supply efficiency in high-throughput settings but necessitate stringent protocols to prevent contamination. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each offer unique access points that influence uptake patterns, patient counseling opportunities, and reimbursement interactions; hospital pharmacies commonly support institutional immunization programs, online pharmacies enable direct-to-consumer access in regulated contexts, and retail pharmacies provide convenient touchpoints for routine immunization. Based on end user, diverse delivery environments such as ambulatory centers, clinics, hospitals, and research facilities impose differing logistical and clinical requirements that manufacturers must account for in product design and support services. Based on age group, adult, geriatric, and pediatric segments drive formulation, dosing, and safety monitoring priorities because immune response and risk profiles vary across the lifespan. Based on application, prophylactic and therapeutic use cases determine evidence needs, with prophylactic vaccination focusing on prevention and population-level protection, while therapeutic applications demand data regarding use in outbreak containment or as adjuncts to clinical care. Collectively, these segmentation dimensions guide targeted product development, tailored messaging for providers and payers, and differentiated commercialization strategies that align with the operational realities of delivery environments.

Regional dynamics that shape regulatory approaches, procurement modalities, manufacturing linkages, and deployment strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics materially influence policy priorities, regulatory approaches, and supply chain architectures for cholera vaccination programs. In the Americas, public health systems tend to emphasize integration of vaccines into established immunization schedules and contingency planning for localized outbreaks, supported by public procurement frameworks that favor transparent contracting and centralized distribution. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory environments and health system capacities, where regional coordination mechanisms and donor-funded initiatives play a large role in harmonizing access and standardizing emergency response protocols.

Meanwhile, the Asia-Pacific region demonstrates a combination of manufacturing capacity growth and large, diverse population needs that create both opportunity and complexity. Across these geographies, regional manufacturers and global suppliers must adapt to varying cold-chain infrastructures, differing regulatory timelines, and distinct stakeholder expectations. As a result, successful strategies increasingly couple technical product attributes with tailored market access plans that reflect local procurement models, reimbursement mechanisms, and public health priorities. Transitional investments in regional distribution hubs and capacity-building programs further influence how quickly and effectively vaccination efforts scale in response to epidemiological signals.

Corporate strategic directions and partnership models that determine competitive advantage through manufacturing scale, platform innovation, and programmatic support commitments

Competitive positioning among leading companies reflects divergent strategies around innovation, supply agreements, and partnerships with public health institutions. Some organizations emphasize platform investments that enable rapid iteration of oral and injectable candidates, while others concentrate on optimizing manufacturing processes and expanding fill-finish capacity to meet the needs of large-scale campaigns. Strategic alliances between commercial manufacturers and global health agencies have become common, focused on jointly addressing affordability, supply predictability, and distribution to hard-to-reach populations.

Additionally, companies that invest in programmatic support services-such as training, cold-chain solutions, and post-market surveillance systems-tend to strengthen their value propositions with national immunization programs and large procurers. Intellectual property strategies and manufacturing licensing arrangements also influence market access; technology transfers to regional producers can accelerate local availability but require careful management of quality assurance and regulatory compliance. Overall, competitive differentiation increasingly rests on the ability to align product attributes with implementation realities, maintain resilient supply networks, and demonstrate commitment to public health outcomes through measurable program support.

Practical and prioritized strategic actions for manufacturers and public health partners to align product design, supply resilience, pricing, and programmatic support for maximal impact

Actionable recommendations for industry leaders emphasize aligning scientific development with practical delivery and stakeholder engagement. First, prioritize product design decisions that account for end-user contexts and distribution realities, ensuring that formulation and packaging choices reduce logistical friction and support rapid outbreak response. Second, invest in diversified supplier networks and regional manufacturing partnerships to mitigate trade and tariff exposure while enhancing responsiveness to local demand. Third, augment commercial offerings with programmatic support such as training, cold-chain innovation, and post-deployment surveillance to strengthen relationships with health authorities and procurers.

Moreover, develop flexible contracting and pricing frameworks that recognize the constraints of public-sector purchasers and international donors, and incorporate contingency clauses that address regulatory or trade disruptions. Finally, commit to transparent data-sharing arrangements and collaborative research partnerships that accelerate evidence generation around real-world effectiveness and safety, thereby building confidence among clinicians, policymakers, and communities. Taken together, these recommendations encourage a balanced approach that integrates scientific rigor, operational resilience, and stakeholder-centered engagement.

A robust mixed-methods research framework combining expert interviews, literature synthesis, and triangulated analysis to ensure evidence-based and actionable insights

The research methodology underpinning this report employed a mixed-methods approach that combined comprehensive literature synthesis, expert interviews, and qualitative analysis of policy and procurement documents. Primary research included structured consultations with vaccine developers, supply chain specialists, and immunization program managers to gather firsthand perspectives on operational challenges and opportunities. Secondary research integrated peer-reviewed studies, regulatory filings, and programmatic guidance to corroborate themes and ensure an evidence-based narrative.

Analytical frameworks emphasized triangulation: insights derived from stakeholder interviews were cross-checked against documented regulatory developments and published clinical outcomes to strengthen validity. Where appropriate, scenario analysis was used to explore operational implications of trade and policy shifts, and sensitivity testing helped highlight potential points of vulnerability in supply networks. Throughout, quality assurance processes ensured that data sources were critiqued for relevance and recency, and that conclusions reflected convergent evidence rather than isolated observations.

A forward-looking conclusion emphasizing the convergence of innovation, supply resilience, and stakeholder collaboration necessary to translate vaccine advances into public health gains

In conclusion, the cholera vaccine domain is at an inflection point where scientific advances, supply chain modernization, and evolving policy demands are converging to reshape how vaccines are developed, procured, and delivered. Innovations in formulation and presentation expand the toolkit available to public health practitioners, while changes in trade and procurement practices remind stakeholders of the need for operational agility. As a result, success will favor organizations that integrate technical excellence with pragmatic programmatic support and resilient commercial strategies.

Looking ahead, sustained collaboration between manufacturers, health authorities, funders, and regional production partners will be essential to translate scientific progress into meaningful reductions in disease burden. By adopting the strategic priorities outlined here-centered on product suitability, supply chain diversification, and stakeholder engagement-actors across the ecosystem can improve preparedness for outbreaks and enhance routine protection. These coordinated efforts will ultimately determine the degree to which vaccine innovations realize their full public health potential.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cholera Vaccines Market, by Vaccine Type

  • 8.1. Injectable Vaccine
  • 8.2. Oral Vaccine

9. Cholera Vaccines Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Oral

10. Cholera Vaccines Market, by Dosage Form

  • 10.1. Liquid
  • 10.2. Lyophilized

11. Cholera Vaccines Market, by Presentation Type

  • 11.1. Multi Dose
  • 11.2. Single Dose

12. Cholera Vaccines Market, by Age Group

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Cholera Vaccines Market, by Application

  • 13.1. Prophylactic
  • 13.2. Therapeutic

14. Cholera Vaccines Market, by End User

  • 14.1. Ambulatory Centers
  • 14.2. Clinics
  • 14.3. Hospitals
  • 14.4. Research Facilities

15. Cholera Vaccines Market, by Distribution Channel

  • 15.1. Hospital Pharmacy
  • 15.2. Online Pharmacy
  • 15.3. Retail Pharmacy

16. Cholera Vaccines Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Cholera Vaccines Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Cholera Vaccines Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Cholera Vaccines Market

20. China Cholera Vaccines Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. AstraZeneca PLC
  • 21.6. Bavarian Nordic A/S
  • 21.7. Bharat Biotech International Limited
  • 21.8. Emergent BioSolutions Inc.
  • 21.9. EuBiologics Co. Ltd.
  • 21.10. GlaxoSmithKline PLC
  • 21.11. Johnson & Johnson
  • 21.12. Merck & Co. Inc.
  • 21.13. Mitsubishi Tanabe Pharma Corporation
  • 21.14. Novartis AG
  • 21.15. PaxVax Inc.
  • 21.16. Pfizer Inc.
  • 21.17. Sanofi Pasteur SA
  • 21.18. Serum Institute of India Pvt. Ltd.
  • 21.19. Shantha Biotechnics Limited
  • 21.20. Takeda Pharmaceutical Company Limited
  • 21.21. Valneva SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHOLERA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHOLERA VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHOLERA VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHOLERA VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHOLERA VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES CHOLERA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA CHOLERA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHOLERA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INJECTABLE VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INJECTABLE VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INJECTABLE VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHOLERA VACCINES MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHOLERA VACCINES MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHOLERA VACCINES MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHOLERA VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHOLERA VACCINES MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHOLERA VACCINES MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHOLERA VACCINES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHOLERA VACCINES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHOLERA VACCINES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AMBULATORY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AMBULATORY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHOLERA VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHOLERA VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHOLERA VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RESEARCH FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RESEARCH FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RESEARCH FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHOLERA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS CHOLERA VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. GCC CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 157. GCC CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GCC CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. G7 CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. G7 CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 184. G7 CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. G7 CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. NATO CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. NATO CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 193. NATO CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. NATO CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. NATO CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. NATO CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES CHOLERA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA CHOLERA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)